Skip to main content
. 2020 Sep 3;14(1):299–309. doi: 10.1111/cts.12868

Figure 2.

Figure 2

Evaluation of drug‐induced serious hepatotoxicity plot for bardoxolone methyl and placebo patients in BEACON. Maximum post‐baseline total bilirubin and alanine aminotransferase (ALT) values for patients randomized to bardoxolone methyl or placebo in Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON). The upper limit of normal (ULN) for total bilirubin is 1.1 mg/dL and the ULN for ALT is 47 (U/L).